Limits...
Diagnostic value of Wilms tumor 1 and CD44 in Langerhans cell sarcoma: case series of 4 patients.

Wang CS, Chen YP, He WH, Yin J, Gao CF, Wang P, Li H, Lv XX - Medicine (Baltimore) (2015)

Bottom Line: Immunochemical antibodies, such as langerin, S-100 protein, and CD1a, have been used to diagnose LCS, but the results are crossed with LCH.To determine more significant biomarkers of LCS, we studied the expression and distribution pattern of Wilms tumor 1 (WT1) and cluster of differentiation 44 (CD44) in LCS.Our results suggest that WT1 and CD44 are potential biomarkers for LCS diagnosis.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Pathology (C-sW, Y-pC, W-hH, JY, PW, X-xL); Institute of Anal-Colorectal Surgery (C-fG), 150th Hospital, Luoyang, Henan; and Department of Otorhinolaryngology and Head-Neck Surgery (HL), Xinqiao Hospital, Third Military Medical University, Chongqing, China.

ABSTRACT
Langerhans cell sarcoma (LCS) is a rare tumor with markedly malignant cytological features originating from Langerhans cells. LCS diagnosis is difficult and requires differentiation from other malignant tumors and Langerhans cell histiocytosis (LCH). Immunochemical antibodies, such as langerin, S-100 protein, and CD1a, have been used to diagnose LCS, but the results are crossed with LCH. To determine more significant biomarkers of LCS, we studied the expression and distribution pattern of Wilms tumor 1 (WT1) and cluster of differentiation 44 (CD44) in LCS. A broad panel of antibodies was used for immunohistochemical technology. Simultaneously, dual immunofluorescence staining examination and fluorescence in situ hybridization staining methods were used to study the location of WT1 and CD44 in LCS tumor cells. The results showed that tumor cells expressed WT1, CD44, and other special Langerhans cell markers (langerin, CD1a, and S-100 protein). LCS cells in all the cases showed normal cytogenetic findings without overexpression of WT1 and CD44. The expression of WT1 and CD44 was observed on langerin tumor cells by dual immunofluorescence staining examination in LCS. Our results suggest that WT1 and CD44 are potential biomarkers for LCS diagnosis. Clear understanding of their functional roles may further explain the pathogenesis of this highly malignant tumor and develop some novel immunotherapy strategies.

Show MeSH

Related in: MedlinePlus

WT1 and CD44 expressed in LCS and LCH. The LCS tumor cells were positive for WT1 (A) and CD44 (C); but LCH tumor cells were negative for WT1 (B) and CD44 (D). CD44 = cluster of differentiation 44, LCH = Langerhans cell histiocytosis, LCS = Langerhans cell sarcoma, WT1 = Wilms tumor 1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4554032&req=5

Figure 2: WT1 and CD44 expressed in LCS and LCH. The LCS tumor cells were positive for WT1 (A) and CD44 (C); but LCH tumor cells were negative for WT1 (B) and CD44 (D). CD44 = cluster of differentiation 44, LCH = Langerhans cell histiocytosis, LCS = Langerhans cell sarcoma, WT1 = Wilms tumor 1.

Mentions: Immunohistochemical staining showed that all 4 cases of LCS tumor cells were positive for WT1 (Figure 2A) and CD44 (Figure 2C). WT1 was observed in the cytoplasm of neoplastic cells, whereas CD44 was found on cell membranes and in the cytoplasm. Ki-67 proliferation index ranged from 70% to 90%. By contrast, the LCH tumor cells were negative for WT1 (Figure 2B) and CD44 (Figure 2D) but positive for CD1a, S-100 protein, and langerin.


Diagnostic value of Wilms tumor 1 and CD44 in Langerhans cell sarcoma: case series of 4 patients.

Wang CS, Chen YP, He WH, Yin J, Gao CF, Wang P, Li H, Lv XX - Medicine (Baltimore) (2015)

WT1 and CD44 expressed in LCS and LCH. The LCS tumor cells were positive for WT1 (A) and CD44 (C); but LCH tumor cells were negative for WT1 (B) and CD44 (D). CD44 = cluster of differentiation 44, LCH = Langerhans cell histiocytosis, LCS = Langerhans cell sarcoma, WT1 = Wilms tumor 1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4554032&req=5

Figure 2: WT1 and CD44 expressed in LCS and LCH. The LCS tumor cells were positive for WT1 (A) and CD44 (C); but LCH tumor cells were negative for WT1 (B) and CD44 (D). CD44 = cluster of differentiation 44, LCH = Langerhans cell histiocytosis, LCS = Langerhans cell sarcoma, WT1 = Wilms tumor 1.
Mentions: Immunohistochemical staining showed that all 4 cases of LCS tumor cells were positive for WT1 (Figure 2A) and CD44 (Figure 2C). WT1 was observed in the cytoplasm of neoplastic cells, whereas CD44 was found on cell membranes and in the cytoplasm. Ki-67 proliferation index ranged from 70% to 90%. By contrast, the LCH tumor cells were negative for WT1 (Figure 2B) and CD44 (Figure 2D) but positive for CD1a, S-100 protein, and langerin.

Bottom Line: Immunochemical antibodies, such as langerin, S-100 protein, and CD1a, have been used to diagnose LCS, but the results are crossed with LCH.To determine more significant biomarkers of LCS, we studied the expression and distribution pattern of Wilms tumor 1 (WT1) and cluster of differentiation 44 (CD44) in LCS.Our results suggest that WT1 and CD44 are potential biomarkers for LCS diagnosis.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Pathology (C-sW, Y-pC, W-hH, JY, PW, X-xL); Institute of Anal-Colorectal Surgery (C-fG), 150th Hospital, Luoyang, Henan; and Department of Otorhinolaryngology and Head-Neck Surgery (HL), Xinqiao Hospital, Third Military Medical University, Chongqing, China.

ABSTRACT
Langerhans cell sarcoma (LCS) is a rare tumor with markedly malignant cytological features originating from Langerhans cells. LCS diagnosis is difficult and requires differentiation from other malignant tumors and Langerhans cell histiocytosis (LCH). Immunochemical antibodies, such as langerin, S-100 protein, and CD1a, have been used to diagnose LCS, but the results are crossed with LCH. To determine more significant biomarkers of LCS, we studied the expression and distribution pattern of Wilms tumor 1 (WT1) and cluster of differentiation 44 (CD44) in LCS. A broad panel of antibodies was used for immunohistochemical technology. Simultaneously, dual immunofluorescence staining examination and fluorescence in situ hybridization staining methods were used to study the location of WT1 and CD44 in LCS tumor cells. The results showed that tumor cells expressed WT1, CD44, and other special Langerhans cell markers (langerin, CD1a, and S-100 protein). LCS cells in all the cases showed normal cytogenetic findings without overexpression of WT1 and CD44. The expression of WT1 and CD44 was observed on langerin tumor cells by dual immunofluorescence staining examination in LCS. Our results suggest that WT1 and CD44 are potential biomarkers for LCS diagnosis. Clear understanding of their functional roles may further explain the pathogenesis of this highly malignant tumor and develop some novel immunotherapy strategies.

Show MeSH
Related in: MedlinePlus